Terconazole is an antifungal drug used to treat vaginal yeast infection. It comes as a lotion or a suppository and disrupts the biosynthesis of fats in a yeast cell. It has a relatively broad spectrum compared to azole compounds but not triazole compounds. Mechanistically, terconazole inhibits fungal lanosterol 14 alpha demethylase, impairing ergosterol formation and causing membrane dysfunction; the molecule shows favorable activity against Candida species commonly responsible for vulvovaginal candidiasis and minimal systemic absorption when applied intravaginally. Formulation choices include ointment or suppository bases designed to maximize local residence time and pH compatibility; stability considerations include susceptibility to hydrolysis under forced conditions and the need to control residual solvents and oxidative impurities during API manufacture.
Parent: Terconazole
Active pharmaceutical ingredient specifications typically require high purity with defined limits for related substances and degradation products. Typical quality specifications used in manufacture and release set assay purity at or above about 98 percent, individual related compounds limited to about 0.2 to 0.5 percent each, and total unspecified impurities limited to about 1.0 percent or less. Related compounds and impurities monitored include positional isomers, N-oxidation products, desalkyl or hydroxylated analogues produced during synthesis or storage, and trace residual solvents from manufacture; specified known impurities are controlled at low parts per hundred levels and residual solvents are controlled to pharmacopeial limits.
Terconazole is used to treat vulvovaginal candidiasis, the fungal infection commonly called a yeast infection. It is applied intravaginally as a cream, lotion, or suppository to deliver the antifungal directly to the affected mucosa.
Terconazole does not treat sexually transmitted bacterial or viral infections. It targets fungal infections such as vaginal candidiasis and is not effective against STDs like chlamydia, gonorrhea, trichomoniasis, herpes, or HIV.
The better option depends on the clinical situation. Fluconazole is an oral systemic azole that can treat vulvovaginal candidiasis with a single or short course oral dose and is useful when systemic therapy is preferred. Terconazole is a topical intravaginal therapy that provides high local concentrations with minimal systemic exposure and may be preferred for localized infections, for patients who cannot take oral azoles, or for some recurrent cases. Efficacy for uncomplicated yeast infections is broadly comparable but choice is guided by patient factors, severity, formulation availability, and prescriber judgment.
Symptom relief is often reported within 24 to 48 hours after starting intravaginal terconazole, with clinical resolution typically occurring within a few days. Complete eradication depends on the formulation and course length; many topical regimens produce resolution within about 3 to 7 days. If symptoms persist or worsen, medical reassessment is recommended.
